Get the Stockscreener App
6.55
1.24%
0.08
Aura Biosciences Inc stock is traded at $6.55, with a volume of 200.42K.
It is up +1.24% in the last 24 hours and down -3.25% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$6.47
Open:
$6.52
24h Volume:
200.42K
Relative Volume:
1.02
Market Cap:
$406.89M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-3.4115
EPS:
-1.92
Net Cash Flow:
$-64.56M
1W Performance:
-2.53%
1M Performance:
-3.25%
6M Performance:
-12.78%
1Y Performance:
-11.37%
1-Day Range:
$6.368
$6.795
1-Week Range:
$6.10
$6.80
52-Week Range:
$4.345
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
6.55 | 415.58M | 0 | -76.41M | -64.56M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Stock (AURA) Latest News
How high can Aura Biosciences Inc. stock goJuly 2025 Pullbacks & Free Safe Capital Growth Stock Tips - Newser
Risk adjusted return profile for Aura Biosciences Inc. analyzed2025 Volume Leaders & Fast Entry Momentum Alerts - Newser
Heatmap analysis for Aura Biosciences Inc. and competitorsEarnings Miss & AI Forecast Swing Trade Picks - Newser
What MACD and RSI say about Aura Biosciences Inc.July 2025 Catalysts & Reliable Price Action Trade Plans - Newser
Will Aura Biosciences Inc. rebound enough to break even2025 Analyst Calls & AI Enhanced Execution Alerts - Newser
What moving averages say about Aura Biosciences Inc.July 2025 Big Picture & Growth Focused Stock Reports - Newser
Is it too late to sell Aura Biosciences Inc.2025 Trade Ideas & Stepwise Trade Signal Implementation - Newser
Identifying reversal signals in Aura Biosciences Inc.2025 Technical Overview & Safe Entry Zone Identification - Newser
Market reaction to Aura Biosciences Inc.’s recent newsWeekly Profit Recap & Capital Efficiency Focused Ideas - Newser
Why Aura Biosciences Inc. stock attracts strong analyst attentionQuarterly Earnings Summary & Fast Exit and Entry Strategy Plans - Newser
Is Aura Biosciences Inc. forming a reversal pattern2025 Winners & Losers & Verified Technical Signals - Newser
Muscle Invasive Bladder Cancer Pipeline 2025: Clinical Trials, Revenue Share, Medication, Treatment Drugs, Companies by DelveInsight - Barchart.com
Full technical analysis of Aura Biosciences Inc. stock2025 Price Momentum & AI Based Trade Execution Alerts - Newser
Aura Biosciences Inc.’s volatility index tracking explainedTake Profit & Safe Capital Growth Trade Ideas - Newser
Top Executive Sells Thousands of Aura Biosciences Shares! - TipRanks
Momentum Traders Eye Aura Biosciences Inc. for Quick BounceQuarterly Trade Report & Weekly Stock Breakout Alerts - newsimpact.co.kr
Aura Biosciences Inc. Shows Support at Fibonacci LevelJuly 2025 Momentum & Fast Gain Stock Tips - metrotimes.co.kr
Aura Biosciences Reports Q2 Results and $75M Financing - MSN
Q3 EPS Estimate for Aura Biosciences Increased by Analyst - Defense World
Is Aura Biosciences Inc. Forming a Bottom PatternPortfolio Profit Report & Verified Chart Pattern Trade Signals - sundaytimes.kr
Understanding Aura Biosciences Inc.’s price movementQuarterly Profit Report & Reliable Intraday Trade Alerts - Newser
Key resistance and support levels for Aura Biosciences Inc.New Guidance & Low Risk Entry Point Tips - Newser
Analysts Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $22.00 - Defense World
Can a trend reversal in Aura Biosciences Inc. lead to recoveryWeekly Trend Recap & Community Trade Idea Sharing Platform - Newser
What institutional flow reveals about Aura Biosciences Inc.July 2025 Reactions & Safe Capital Growth Plans - Newser
Regression analysis insights on Aura Biosciences Inc. performanceAnalyst Downgrade & Risk Managed Trade Strategies - Newser
Combining price and volume data for Aura Biosciences Inc.July 2025 Price Swings & High Return Trade Guides - Newser
Q3 EPS Forecast for Aura Biosciences Lowered by Analyst - Defense World
Can Aura Biosciences Inc. rally from current levelsEarnings Overview Summary & Low Volatility Stock Suggestions - Newser
Optimistic Buy Rating for Aura Biosciences Inc: Promising Pipeline, Strategic Positioning, and Strong Financials - TipRanks
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth - Yahoo Finance
HC Wainwright Reaffirms “Buy” Rating for Aura Biosciences (NASDAQ:AURA) - Defense World
Aura Biosciences Posts Q2 Cash Surge - AOL.com
Aura Biosciences Advances Clinical Trials and Strengthens Finances - TipRanks
Certain Warrants of Aura Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 14-AUG-2025. - MarketScreener
Aura Biosciences shares fall 1.94% after-hours following second quarter 2025 financial results. - AInvest
Aura Biosciences Inc: Promising Clinical Developments and Strong Financial Position Support Buy Rating - TipRanks
Aura Biosciences shares rise 4.04% intraday after reporting earnings results for August 2025. - AInvest
Aura Biosciences Inc’s Promising Clinical Advancements and Strategic Positioning Justify Buy Rating - TipRanks
Positive Outlook on Aura Biosciences: Strategic Developments and Promising Trials Drive Buy Rating - NewsBreak: Local News & Alerts
Aura Biosciences: A Strategic Play in High-Unmet-Need Ocular and Urologic Oncology - AInvest
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aura Biosciences Inc Stock (AURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Elazzouzi Amy | Senior Vice President, Finance |
Aug 18 '25 |
Sale |
6.70 |
7,722 |
51,737 |
86,558 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):